


# NEW DATA & NEW TREATMEMTS

## CNS Activity of T-DXd in Pts with Active BM







TUXEDO-1 trial Bartsch et al, Nat Med 2022

ORR-IC = 73% in pts with active BM

DEBBRAH trial Perez-Garcia et al, Neuro Oncol 2022

ORR-IC =46% in pts with active BM

DFCI/Duke/MDACCC series Kabraji et al, Clin Ca Res 2022, in press


ORR-IC =73% (70% in pts with active BM)

### DESTINY-Breast12

#### **Study Design and Population**

#### Patient population (N≈500)

- HER2-positive advanced or metastatic breast cancer
- Absence or presence of BM at baseline
- ≤2 prior lines of therapy in the metastatic setting



#### HER2 TKI + ADC Combinations

HER2CLIMB02: TDM1 +/- tucatinib

TBCRC 022: TDM1 + neratinib HER2CLIMB04:

TDXd + tucatinib

Phase 1b ZN1041 + HER2 therapies (TDM1, TDXd, HP)